Sponsors (107)
The bill centralizes and standardizes how Medicare sets lab-test payment rates to improve consistency, transparency, and continuity of payments, but it also creates new market-concentration, administrative, privacy, and dispute-related risks that could raise costs and cause temporary payment uncertainty.
Clinical laboratories, hospitals/health systems, and payors will have Medicare payment rates for lab tests set from a single certified national claims database, improving consistency, transparency, and allowing labs to verify and challenge rate calculations.
Patients who rely on regular lab testing and the labs that serve them gain protection against abrupt payment interruptions because a default inflation-based payment rule preserves continuity if data access or validation fails.
Medicare's requirement to use a single certified national nonprofit claims database could concentrate market power, creating switching costs and risks of vendor dominance that hurt smaller data providers and increase long-term costs.
New data reporting, validation, and certification requirements will raise administrative burdens and compliance costs for payors and data entities, which could be passed on to taxpayers, employers, or consumers.
Relying on private-payor claims and tighter validation may lead to contract or validation disputes that delay Medicare rate-setting and create temporary uncertainty in lab payments despite the default rule.
Based on analysis of 2 sections of legislative text.
Requires Medicare to contract with a qualifying independent nonprofit comprehensive claims database and use it to set payments for widely available non-ADLT clinical lab tests, phased in 2027–2028.
Requires Medicare to change how it gathers private-payor claims data used to set payment rates for widely available non-Advanced clinical diagnostic laboratory tests. The bill phases in new rules that direct the Secretary of HHS to contract with a qualifying independent nonprofit comprehensive claims database operator and to use that database for setting payments beginning in reporting periods in 2027–2028, with revised definitions and reporting timing.
Official title: To amend title XVIII of the Social Security Act to provide long-term stability for Medicare beneficiary access to clinical diagnostic laboratory tests by improving the accuracy of, and feasibility of data collection for, the private payor-based fee schedule payment rates applied under the Medicare program for such tests, and for other purposes.
Introduced September 10, 2025 by Richard Hudson · Last progress September 10, 2025